Skip to main content

Valliant John's Form 4 filing

Fusion Pharmaceuticals Inc. (FUSN) · filed Mar 14, 2022

Accession no.
0001209191-22-018455
Filed
Mar 14, 2022
Trade date
Mar 9-11, 2022
Filing delay
5 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market sales total $19.8K. It was filed 5 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Valliant JohnCIK 0001813574Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 9, 2022Common StockSSaleDisposed−822$6.94F2−$5,704.68389,464Direct
Mar 10, 2022Common StockSSaleDisposed−1,900$7.06F3−$13,414387,564Direct
Mar 11, 2022Common StockSSaleDisposed−100$7.13F4−$713387,464Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.82 to $7.08 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $6.92 to $7.25 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.11 to $7.30 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)